A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

a study on Multiple Myeloma

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Sandy Wong

Description

Summary

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Official Title

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Details

This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46 in patients with relapsed or refractory multiple myeloma. This study will be conducted in two parts:

Dose escalation:

This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once this dose is shown to be safe, a second patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD is reached.

Dose expansion:

This part of the study will further evaluate the safety, tolerability and antitumor activity of FOR46 at a dose shown to be safe in the dose escalation part of the study.

Keywords

Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma With Failed Remission Neoplasms, Plasma Cell FOR46

Eligibility

You can join if…

Open to people ages 18 years and up

  • Male or female ≥ 18 years of age
  • Measurable MM that is relapsed or refractory to established therapies with known clinical benefit in RRMM or intolerant of those established MM therapies. Prior lines of therapy must include a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD) and a CD38-directed therapy in any order of combination.
  • ECOG performance status of 0 or 1
  • Adequate hematologic, renal and hepatic function
  • Females of child-bearing potential must have a negative serum pregnancy test and use a medically acceptable form of contraception
  • Male patients with with female partners of childbearing potential must agree to use 2 effective methods of contraception
  • Patients must provide signed informed consent

You CAN'T join if...

  • Persistent clinically significant toxicities from previous anticancer therapy
  • NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology
  • Has received treatment with a stem cell transplant within 12 weeks before administration of patient's first dose of FOR46
  • Has had radiation or systemic anticancer therapy within 14 days before first dose of FOR46
  • Has received treatment with an investigational drug within 28 days before first dose of FOR46
  • Clinically significant cardiovascular disease
  • Uncontrolled, clinically significant pulmonary disease
  • Uncontrolled intercurrent illness
  • Requires medications that are strong inhibitors or strong inducers of CYP3A4

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center accepting new patients
    San Francisco California 94143 United States
  • Washington University in St. Louis-Siteman Cancer Center accepting new patients
    Saint Louis Missouri 63310 United States

Lead Scientist

  • Sandy Wong
    Assistant Professor, Medicine. Authored (or co-authored) 16 research publications. Research interests: amyloidosis · plasma cell dyscrasias · multiple myeloma · MGUS · SMM

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Fortis Therapeutics, Inc.
ID
NCT03650491
Phase
Phase 1
Study Type
Interventional
Last Updated